Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00658736 · ClinicalTrials.gov registry record · Phase 3
Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis
A Phase 3 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT00658736 is a Phase 3 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 40 participants.
The verdict
NCT00658736, a Phase 3 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a triple-blind, parallel group, randomized controlled trial to assess the benefit of triamcinolone injection as a therapeutic measure for control of chronic pancreatitis pain. The treatment group will undergo EUS-CPB with bupivicaine plus triamcinolone ("therapeutic block"). There control group will undergo EUS-CPB with bupivicaine alone ("diagnostic block").
Interventions
- DRUG Triamcinolone
- DRUG Bupivicaine alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-03 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00658736
The ClinicalTrials.gov registry entry for NCT00658736 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Triamcinolone is the first listed.
NCT00658736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00658736 about?
NCT00658736 is a clinical study titled "Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis". This is a triple-blind, parallel group, randomized controlled trial to assess the benefit of triamcinolone injection as a therapeutic measure for control of chronic pancreatitis pain. The treatment group will undergo EUS-CPB with bupivicaine plus triamcinolone ("therapeutic block"). There control gr...
What is the current status of trial NCT00658736?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2008-03. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00658736?
The interventions under investigation include: Triamcinolone (DRUG), Bupivicaine alone (DRUG).
Who is sponsoring clinical trial NCT00658736?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.